These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Treatment of haemorrhage with transfusion preparations and blood derivatives]. Buliková A; Matýsková M; Penka M Vnitr Lek; 2008 Jun; 54(6):623-31. PubMed ID: 18672574 [TBL] [Abstract][Full Text] [Related]
26. [Duration of life of the fibrin stabilizing factor (factor 13). Therapeutic indications]. Josso F; Petrova M; Ménaché D; Sizonenko P Transfusion (Paris); 1966; 9(4):343-6. PubMed ID: 5966234 [No Abstract] [Full Text] [Related]
27. [Blood coagulation changes under the effect of blood transfusions in patients with infiltrative pulmonary tuberculosis]. Sukhov VM Probl Tuberk; 1969; 47(10):43-6. PubMed ID: 5375700 [No Abstract] [Full Text] [Related]
28. Blood transfusion: merits of component therapy. II. The clinical use of plasma and plasma components. Buchholz DH J Pediatr; 1974 Feb; 84(2):165-72. PubMed ID: 4589841 [No Abstract] [Full Text] [Related]
29. [The patient with coagulation disorders in dentistry]. Schneider W ZWR; 1974 Oct; 83(19):992-7. PubMed ID: 4548276 [No Abstract] [Full Text] [Related]
30. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease. Spector I; Corn M; Ticktin HE N Engl J Med; 1966 Nov; 275(19):1032-7. PubMed ID: 5923337 [No Abstract] [Full Text] [Related]
31. Disseminated intravascular coagulation. How often have you missed it? Peck SD Rocky Mt Med J; 1970 Oct; 67(10):25-31. PubMed ID: 5472049 [No Abstract] [Full Text] [Related]
32. The therapy of factor 13 deficiency. Duckert F Bibl Haematol; 1965; 23():1354-7. PubMed ID: 5885230 [No Abstract] [Full Text] [Related]
33. The hematologic effects of cardiopulmonary bypass and the use of hemotherapy in coronary artery bypass grafting. Bracey AW; Radovancević R Arch Pathol Lab Med; 1994 Apr; 118(4):411-6. PubMed ID: 8166591 [TBL] [Abstract][Full Text] [Related]
34. Disorders of hemostasis in acute leukemia: part II. Al-Mondhiry H Clin Bull; 1975; 5(2):51-6. PubMed ID: 1227733 [No Abstract] [Full Text] [Related]
35. Blood component therapy for abnormalities of hemostasis in liver disease. Glassman AB Conn Med; 1972 Oct; 36(10):572-5. PubMed ID: 5086117 [No Abstract] [Full Text] [Related]
36. The treatment of coagulation factor deficiencies. Temperley IJ J Ir Med Assoc; 1973 Jan; 66(2):42-5. PubMed ID: 4688930 [No Abstract] [Full Text] [Related]
37. Detection and treatment of severe coagulation disturbances in the neonatal period. Thomas DB Med J Aust; 1974 Jun; 1(24):962-4. PubMed ID: 4851307 [No Abstract] [Full Text] [Related]
38. Congenital deficiency of factor 13 (fibrin-stabilizing factor): Report of a case and review of the literature. Britten AF Am J Med; 1967 Nov; 43(5):751-61. PubMed ID: 6054840 [No Abstract] [Full Text] [Related]
39. [Effect of intravenous infusions of thrombin and heterogenous blood on lymph coagulability]. Kuznik BI; Mishchenko VP; Budazhabon GV; Tsybikov NN Fiziol Zh SSSR Im I M Sechenova; 1976 Oct; 62(10):1460-5. PubMed ID: 1017512 [TBL] [Abstract][Full Text] [Related]
40. [Main principles of effective hemotherapy]. Dobrý E Cas Lek Cesk; 1968 Nov; 107(47):1436-8. PubMed ID: 5696569 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]